Cancer Clinical Investigation

Medicine & Life Sciences

1. 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 8%
2. Acute Myeloid Leukemia 12%
3. Azacitidine 11%
4. Biomarkers 22%
5. Biopsy 9%
6. Bone Marrow 13%
7. Bortezomib 16%
8. Breast Neoplasms 14%
9. Carcinoma 30%
10. carfilzomib 16%
11. Castration 11%
12. Chimeric Antigen Receptors 9%
13. Cholangiocarcinoma 15%
14. Cisplatin 16%
15. Clinical Trials 23%
16. Confidence Intervals 15%
17. Coronavirus 12%
18. Cystectomy 17%
19. daratumumab 17%
20. Databases 11%
21. Datasets 12%
22. Dendritic Cells 16%
23. Dexamethasone 19%
24. Drug Therapy 30%
25. Epigenomics 16%
26. Essential Thrombocythemia 11%
27. Fibrosis 14%
28. Gene Expression 10%
29. Genes 22%
30. Genome 8%
31. Graft vs Host Disease 13%
32. Growth 8%
33. Head and Neck Neoplasms 12%
34. Hematopoietic Stem Cells 17%
35. Hepatocellular Carcinoma 100%
36. Immunotherapy 25%
37. INCB018424 20%
38. Incidence 11%
39. Janus Kinase Inhibitors 10%
40. Kidney 11%
41. Lenalidomide 19%
42. Leukemia 9%
43. Ligands 11%
44. Liver 39%
45. Liver Diseases 9%
46. Liver Neoplasms 15%
47. Liver Transplantation 36%
48. Living Donors 9%
49. Lung Neoplasms 13%
50. Magnetic Resonance Imaging 12%
51. Melanoma 8%
52. Meta-Analysis 10%
53. Mortality 11%
54. Multiparametric Magnetic Resonance Imaging 12%
55. Multiple Myeloma 89%
56. Muscles 9%
57. Mutation 19%
58. Myelodysplastic Syndromes 16%
59. Neoplasm Metastasis 12%
60. Neoplasms 95%
61. Nivolumab 9%
62. Non-Small Cell Lung Carcinoma 10%
63. ON 01910 10%
64. Oropharyngeal Neoplasms 10%
65. Pandemics 9%
66. Pharmaceutical Preparations 16%
67. Phosphotransferases 13%
68. Platinum 10%
69. Polycythemia Vera 24%
70. Population 10%
71. Primary Myelofibrosis 50%
72. Progression-Free Survival 19%
73. Prostate 13%
74. Prostatectomy 16%
75. Prostatic Neoplasms 38%
76. Proteins 17%
77. Proteogenomics 12%
78. Proteomics 11%
79. Quality of Life 9%
80. Radiation 10%
81. Radiotherapy 17%
82. Recurrence 23%
83. Renal Cell Carcinoma 10%
84. Robotics 15%
85. Safety 18%
86. selinexor 13%
87. Sorafenib 18%
88. Squamous Cell Carcinoma of Head and Neck 11%
89. Stem Cells 13%
90. Survival 58%
91. Systematic Reviews 10%
92. T-Lymphocytes 21%
93. Therapeutics 57%
94. Thrombocytopenia 8%
95. Tissue Donors 9%
96. Transcriptome 10%
97. Transplantation 11%
98. Transplants 19%
99. Tumor Microenvironment 9%
100. Urinary Bladder Neoplasms 33%